Background Several genetic aberrations with prognostic impact in first-line therapy have been described in patients with acute myeloid leukemia and normal karyotype. However, little is known about the influence of these aberrations on outcome after relapse. This study aimed to identify clinical and molecular risk factors for patients with relapsed acute myeloid leukemia with normal karyotype.
Introduction
Approximately 50% of patients with acute myeloid leukemia (AML) have a cytogenetically normal (CN) form of the disease; that is, no chromosomal aberrations can be detected by standard cytogenetics. In recent years, a wide variety of somatic gene mutations has been described in these patients. 1, 2 The most frequent of these mutations affect the nucleophosmin gene, NPM1, and are present in approximately 50% of cases of CN-AML. 3 Internal tandem duplications (ITD) in the cytokine receptor gene FLT3 are also very common, occurring in approximately 20-30% of cases of CN-AML. In addition, loss-of-function mutations in the Wilms' tumor gene, WT1, the CEBPA gene which encodes for the myeloid transcription factor C/EBPα and mutations in the isocitrate dehydrogenase genes 1 and 2 (IDH1 and IDH2) (all present in approximately 10% of CN-AML) have been described. [4] [5] [6] [7] [8] The prognostic impact of these aberrations in CN-AML has been analyzed at initial diagnosis and was found to be very strong. Patients with an NPM1 mutation in the absence of an FLT3-ITD and patients with a CEBPA mutation have a significantly better prognosis than patients who either harbor an FLT3-ITD or are negative for all three genetic aberrations. 9, 10 While these findings have been confirmed in several studies, analyses of the prognostic impact of mutations in WT1, IDH1 and IDH2 have produced conflicting results. [6] [7] [8] 11, 12 In contrast, little is known about the prognostic value of gene mutations in patients with relapsed disease. Relapse occurs in approximately 50-60% of patients with CN-AML who achieve a complete remission and there is no clearly defined therapeutic standard for these patients. 13, 14 The spectrum of therapeutic options in these patients ranges from intensive re-induction therapy combined with allogeneic stem cell transplantation to experimental approaches or best supportive care. The identification of easily accessible prognostic factors for survival after relapse is needed since these might be able to serve as a basis for risk stratification and choice of therapy in these patients. We, therefore, performed a comprehensive analysis of 94 patients with relapsed CN-AML. These patients had been treated firstline with a uniform protocol within two successive multicenter trials. 15 Pretreatment samples from the patients had been extensively analyzed for gene mutations and polymorphisms with known prognostic impact.
Design and Methods

Patients' characteristics
All patients analyzed were treated within the multicenter treatment trials AML SHG 295 (February 1995 to May 1999) or AML SHG 0199 (ClinicalTrials Identifier NCT00209833, June 1999 to September 2004). These trials included adult patients (aged 17-60 years at initial diagnosis, median age 47 years) with de novo or secondary AML (French-American British [FAB] classification M0-M2, M4-M7). Both treatment protocols included intensive, response-adapted double induction and consolidation therapy and details have been previously reported. 15, 16 Patients for this analysis were selected according to the following criteria: (i) normal karyotype on cytogenetic analysis at diagnosis; (ii) relapse after achievement of a complete remission according to accepted criteria; (iii) intensive salvage treatment after relapse; and (iv) availability of bone marrow or peripheral blood samples from the time of initial diagnosis for molecular analysis. These criteria were fulfilled by 94 patients (28 from the AML SHG 295 trial and 66 from the AML-SHG 0199 trial). Written informed consent to participation in the study was obtained from the patients according to the Declaration of Helsinki, and the study was approved by the institutional review board of Hannover Medical School.
Cytogenetic and molecular analyses
Pretreatment samples from all patients were studied centrally by G-or R-banding analysis. At least 20 metaphases were analyzed. Chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature. Various genes were assessed for frequently occurring mutations and expression, as previously described (i. ).
Statistical analysis
Complete remission and remission duration were defined according to recommended criteria. 18 The median follow-up time for survival after relapse was calculated according to the method of Korn. 19 The primary end-point of the analysis was survival after relapse, measured from the date of documented relapse until death (treatment failure) or last follow-up for those still alive (censored). Pairwise comparisons of variables for exploratory purposes were performed using the Mann-Whitney-test or the χ 2 -test. The Kaplan-Meier method and log-rank test were used to estimate the distribution of survival after relapse, and to compare differences between survival curves, respectively. Mutations/polymorphisms in the analyzed genes (FLT3, NPM1, WT1, CEBPA, IDH1, and IDH2) were used as categorical variables. Expression of WT1 mRNA was used either as a continuous variable or dichotomized at the median expression value (median normalized copy number, gene transcripts per ABL transcripts). The duration of first complete remission was dichotomized into less than 6 months and 6 months or more. For multivariate analysis, a Cox proportional hazards model was constructed for survival after relapse. Variables with P values of 0.1 or less in univariate analysis were included in the model. A conditional backwards-elimination procedure was used to exclude redundant or unnecessary variables. A logistic regression model was used to analyze associations between variables and response to re-induction therapy. To provide quantitative information on the relevance of results, 95% confidence intervals (95% CI) of odds ratios (OR) and hazard ratios (HR) were computed. Multivariate analysis of survival after relapse was the primary analysis, all other analyses were considered exploratory. Statistics were performed with the SPSS version 16.0 software package.
Results
Patients' characteristics and molecular aberrations
Out of 149 relapsed patients, 94 fulfilled the selection criteria. The outcome and clinical characteristics of these patients were not significantly different from those of the relapsed patients not included in this analysis because specimens were not available (n=51, data not shown). The clinical characteristics and results of the molecular analysis of the analyzed patients are presented in Table 1 . The frequency of the different molecular aberrations was 50% for NPM1 mutations, 30% for FLT3-ITD, 12% for IDH1 mutations, 12% for IDH2 mutations, 12% for WT1 mutations and 9% for CEBPA mutations.
Response to salvage treatment
Of the 94 relapsed patients, 77 received intensive, cytarabine-based re-induction chemotherapy and 17 patients underwent allogeneic stem cell transplantation directly, without prior re-induction (5 patients received grafts from matched, related donors and 12 patients received grafts from unrelated donors). Of the 77 patients who underwent re-induction treatment, 40 (52%) achieved a second complete remission. In univariate analysis the presence of an FLT3-ITD (second complete remission rate 22% versus 64%, P=0.001), NPM1/FLT3-high risk status (second complete remission rate 41% versus 73%, P=0.022), duration of first complete remission less than 6 months (second complete remission rate 18% versus 65%, P<0.0001) and age above the median (second complete remission rate 38% versus 69%, P=0.012) had a negative impact on the achievement of a second complete remission. There was also a trend towards a lower second complete remission rate in patients with high WT1-expression (second complete remission rate 40% versus 63%, P=0.06). The other clinical and molecular parameters listed in Table 1 did not influence the second complete remission rate. In multivariate analysis, the presence of an FLT3-ITD, duration of first complete remission and age were the only independent risk factors for the achievement of second complete remission ( Table 2 ).
Survival after relapse
The median follow-up for survival after relapse was 65 months (95% CI, 46 -86 months). Of the 94 patients studied, 65 died resulting in a median survival after relapse of 11 months and a 6-year rate of survival after relapse of 28% (95% CI, 23% -33%; Figure 1A ). Univariate analysis revealed that FLT3-ITD, age, WT1-expression, duration of first complete remission and the WT1 SNP rs16754 were significant prognostic factors for survival after relapse. Other clinical or molecular parameters had no effect on survival after relapse (Table 3) . In multivariate analysis, age and the presence of an FLT3-ITD were the only independent risk factors for survival after relapse (Table 4 ). This was also true when only the 85 patients who did not receive an allogeneic stem cell transplantation in first complete remission were included in the analysis (data not shown). The univariate Kaplan-Meier analysis for these risk factors is shown in Figure 1B and C.
When these two risk factors were combined into a risk score, three groups of patients with significantly different survival after relapse could be separated: the median survival after relapse of patients without any of these characteristics has not been reached and the 6-year survival after relapse rate is 56%; patients with one of these factors had a median survival after relapse of 11 months and a 6-year survival rate after relapse of 15%, while patients with both risk factors had a median survival after relapse of 4.5 months and a 6-year survival rate after relapse of 6% (Figure 2A) . The outcome of patients with none of these risk factors was still significantly better than that of patients with one or two risk factors when only patients who received re-induction chemotherapy (data not shown) or patients who underwent allogeneic stem cell transplantation after relapse ( Figure 2B ) were considered. 
Discussion
Prospective data on prognostic factors in patients with relapsed AML are limited.
14 In previous studies, age at relapse, duration of first complete remission, stem cell transplantation in first complete remission and cytogenetics at diagnosis were associated with outcome after relapse. 20 However, little is known about the impact of gene mutations and polymorphisms in patients with relapsed AML and a normal karyotype. We, therefore, investigated whether some of these mutations are of prognostic value not only at initial diagnosis but also after relapse. We analyzed a cohort of 94 patients with relapsed CN-AML. These patients were treated within two consecutive multicenter trials and prospective follow-up continued after relapse. All analyzed patients received intensive re-induction therapy and/or underwent allogeneic stem cell transplantation after relapse. Thus, the prognostic impact of molecular aberrations could be evaluated in the context of intensive salvage therapy.
Fifty-two percent of the patients who received re-induction therapy achieved a second remission. This is within the expected range for this population of patients. [20] [21] [22] Prognostic factors for the achievement of a second complete remission were age of the patient, the duration of first complete remission and -as the only molecular marker -the presence of an FLT3-ITD at initial diagnosis. Similar results were reported by Ravandi et al. 21 and Boissel et al. 23 However, in both studies molecular aberrations apart from FLT3-ITD were not taken into account and the analysis by Boissel et al. also included patients with other karyotypes. The significantly inferior second complete remission rate of FLT3-ITD-positive patients is of interest since in several large studies the presence of an FLT3-ITD was not associated with an inferior complete remission rate after first-line induction therapy. 4, 24, 25 Thus, compared to cells from other subgroups of CN-AML, leukemic cells harboring an FLT3-ITD might be especially prone to acquire chemoresistance during the course of disease, e.g. by an increase in the ratio of mutant-to-wildtype alleles. 26 In addition to the second complete remission rate, we also analyzed the effect of clinical characteristics and molecular markers on long-term outcome of the patients. As the primary endpoint, we chose survival from the time of relapse to exclude an effect of the duration of first complete remission on the analysis. 20 In multivariate analysis, age and the presence of an FLT3-ITD were the only factors with an impact on survival. Other molecular markers with an accepted impact on prognosis at initial diagnosis such K. Wagner et al. 684 haematologica | 2011; 96(5) as CEBPA mutations or combined NPM1/FLT3 mutational status had no impact on survival after relapse. Somatic mutations in CN-AML show different degrees of stability during disease progression: NPM1 and CEBPA mutations seem to be stable genetic events. 27, 28 Data on the stability of IDH1/2 mutations are limited. In six patients with IDH1/2 mutations for whom we could analyze paired samples taken at diagnosis and at relapse, the same mutation was present at relapse and in none of 16 IDH1/2 wild-type patients was a mutation acquired at relapse (data not shown). In contrast, the mutational status of WT1 or FLT3 might be different at initial diagnosis and at relapse in some patients. 26, [29] [30] [31] It is, therefore, compelling that the presence of an FLT3-ITD at initial diagnosis was still the only molecular aberration with a prognostic impact after relapse in our analysis. Thus, in addition to its own role in leukemogenesis, FLT3-ITD might also be a surrogate marker for high-risk characteristics of leukemic cells which persist, although the ITD is no longer detectable in the bulk leukemic population.
When we combined age and FLT3-ITD status in a prognostic score, three groups of patients with significantly different survival could be separated: the 6-year survival rate of patients with none of these risk factors was 56%, whereas the prognosis of patients with one or two of these risk factors was dismal with the patients' 6-year survival rate being 15% and 6%, respectively. Importantly, this was also true when only patients who underwent allogeneic stem cell transplantation after relapse were considered. Thus it appears that the antileukemic effect of allogeneic stem cell transplantation might not be able to overcome the adverse impact of FLT3-ITD and/or age. The numbers of patients with one or two risk factors were small in the subset of patients who had undergone allogeneic stem cell transplantation after relapse. However, if this finding is confirmed in further trials, it challenges the role of standard allogeneic stem cell transplantation in the salvage therapy of these patients. Collectively, our data show that FLT3-ITD and age were major prognostic factors in our cohort of patients with relapsed CN-AML. Younger FLT3-ITD-negative patients had a high chance of successful salvage after re-induction chemotherapy and allogeneic stem cell transplantation. In contrast, the outcome of FLT3-ITD-positive patients -especially if they were older -was dismal and such patients might be considered candidates for investigational approaches. Of special interest for the FLT3-ITD-positive patients in this respect are novel tyrosine kinase inhibitors which have shown promising activity in early trials although their optimal schedule for single agent application and combination with chemotherapy has yet to be defined. [32] [33] [34] [35] [36] These agents might be able to improve the outcome of certain subgroups of patients in the future. 
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